Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001)

Table 2 Individual patient profiles of baseline characteristics

Targeted neuromuscular diseases	Patient ID	Group	Age (years)	Barthel Index (0–100)	2MWT (m)	Total MMT scores (0–60)
Spinal muscular atrophy	1-3	A	52	95	116.3	35
	6-1*	A	48	100	97.3	37
	6-2*	A	57	90	66.5	30
	1-1	B	59	85	39.3	33
	9-6	B	57	60	68.6	28
Spinal bulbar muscular atrophy	1-2	A	64	80	41.9	36
Spinal bulbar muscular atrophy	5-1*	A	54	60	30.1	39
Amyotrophic lateral sclerosis	3-2	A	69	25	30.3	26
Charcot Marie Tooth disease	9-3	A	76	95	120.1	39
	8-1	B	55	95	55.3	31
	8-2	B	63	85	126.5	37
Myotonic dystrophy	9-2	B	65	90	75.3	32
Myotonic dystrophy	9-4	B	51	90	90.4	28
Distal myopathy with RV	2-3*	B	40	100	87.7	24
Distal myopathy, Myoshi	2-4*	A	50	80	78.3	23
	5-3*	A	63	65	25.0	31
	2-2	B	58	90	85.2	30
	7-2*	B	47	85	59.7	36
FSH-type muscular dystrophy	1-4*	A	40	90	56.8	37
	2-7	A	46	75	57.3	29
	2-6	B	51	85	79.1	31
Other limb girdle-type muscular dystrophy	2-5*	A	33	55	97.1	26
Other limb girdle-type muscular dystrophy	9-7	B	65	65	48.3	29
Sporadic inclusion body myositis	3-1*	A	76	65	61.7	34

The patient ID indicates site number-patient number. An asterisk (*) in a patient’s ID indicates the outpatient status during the study period

ISSN: 1750-1172